Mazuski John E, Sawyer Robert G, Nathens Avery B, DiPiro Joseph T, Schein Moshe, Kudsk Kenneth A, Yowler Charles
Department of Surgery, Saint Louis University School of Medicine, St. Louis, MO 63110-1093, and Bronx Lebanon Hospital Center, Bronx, NY, USA.
Surg Infect (Larchmt). 2002 Fall;3(3):175-233. doi: 10.1089/109629602761624180.
Revised guidelines for the use of antimicrobial therapy in patients with intra-abdominal infections were recently developed by the Therapeutic Agents Committee of the Surgical Infection Society (Mazuski et al., Surg Infect 2002;3:161-173). These were based, insofar as possible, on evidence published over the past decade. The objective of this document is to describe the process by which the Committee identified and reviewed the published literature utilized to develop the recommendations and to summarize the results of those reviews. English-language articles published between 1990 and 2000 related to antimicrobial therapy for intra-abdominal infections were identified by a systematic MEDLINE search and an examination of references included in recent review articles. If current literature with regard to a specific issue was lacking, relevant articles published prior to 1990 were identified. All prospective randomized controlled trials, as well as other articles selected by the Committee, were evaluated individually and collectively. Data with regard to patient numbers, types of infections, and results of interventions were abstracted. Studies were categorized according to their design, and all included trials were graded according to quality. On the basis of this evidence, the Committee formulated recommendations for antimicrobial therapy for intra-abdominal infections and graded those recommendations. After receiving comments from invited reviewers and the general membership of the Society, the guidelines were finalized and submitted to the Council of the Surgical Infection Society for approval. The final recommendations related to the selection of patients needing therapeutic antimicrobials, acceptable antimicrobial regimens, duration of antimicrobial use, and the identification and treatment of higher-risk patients. Although numerous publications pertaining to these topics were identified, but nearly all of the prospective randomized controlled trials represented comparisons of different antimicrobial regimens for the treatment of intra-abdominal infections. A few prospective trials evaluated the need for therapeutic antimicrobial therapy in patients with peritoneal contamination following abdominal trauma. The quality of these prospective trials was highly variable. Many did not limit enrollment to patients with complicated intra-abdominal infections, lacked blinding of treatment assignment, did not provide a complete description of the criteria used to determine therapeutic success or failure, failed to identify the reasons why patients were excluded from analysis, or did not include an intention-to-treat analysis. For many issues, no prospective randomized controlled trials were encountered, and guidelines had to be formulated using evidence from studies with historical controls or uncontrolled data, or on the basis of expert opinion
外科感染协会治疗药物委员会最近制定了腹内感染患者抗菌治疗的修订指南(马祖斯基等人,《外科感染》2002年;3:161 - 173)。这些指南尽可能基于过去十年发表的证据。本文的目的是描述委员会识别和审查用于制定这些建议的已发表文献的过程,并总结这些审查的结果。通过系统的医学文献数据库(MEDLINE)检索以及查阅近期综述文章中包含的参考文献,确定了1990年至2000年间发表的与腹内感染抗菌治疗相关的英文文章。如果缺乏关于特定问题的当前文献,则确定1990年之前发表的相关文章。所有前瞻性随机对照试验以及委员会挑选的其他文章都进行了单独和综合评估。提取了有关患者数量、感染类型和干预结果的数据。研究根据其设计进行分类,所有纳入的试验根据质量进行分级。基于这些证据,委员会制定了腹内感染抗菌治疗的建议并对这些建议进行了分级。在收到特邀审稿人和协会普通会员的意见后,指南最终确定并提交给外科感染协会理事会批准。最终建议涉及需要治疗性抗菌药物的患者的选择、可接受的抗菌方案、抗菌药物使用的持续时间以及高风险患者的识别和治疗。虽然识别出了许多与这些主题相关的出版物,但几乎所有前瞻性随机对照试验都是不同抗菌方案治疗腹内感染的比较。一些前瞻性试验评估了腹部创伤后腹膜污染患者进行治疗性抗菌治疗的必要性。这些前瞻性试验的质量差异很大。许多试验没有将入组限制在复杂性腹内感染患者,缺乏治疗分配的盲法,没有完整描述用于确定治疗成功或失败的标准,没有说明患者被排除分析的原因,或者没有进行意向性分析。对于许多问题,没有遇到前瞻性随机对照试验,指南不得不根据有历史对照或无对照数据的研究证据或专家意见来制定